Clinical Trials
CytoDyn Receives IRB Approval to Initiate Phase 2 Basket Trial for 22 Solid Tumor Cancers
CytoDyn Inc , a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, reported that it has received Institutional Review Board (IRB) approval to begin its Phase 2 clinical trial for...
Clinical Trials
Biocons Insulin Manufacturing Facility in Malaysia Completes U.S. FDA Inspection
This is to inform you that the U.S. FDA conducted a pre-approval inspection (PAI) of our subsidiary, Biocon Sdn. Bhd’s Insulins manufacturing facility based in Malaysia, for Insulin Glargine, between Feb 10 and Feb 21, 2020.
At the conclusion of...
Clinical Trials
Spring Bank Pharmaceuticals in Clinical Collaboration With Roche
Spring Bank Pharmaceuticals Inc. said it has entered into a new clinical collaboration with Roche to explore the co-administration of SB 11285, Spring Bank's intravenously-administered stimulator of interferon gene agonist with Roche's PD-L1 checkpoint inhibitor atezolizumab in patients with...
Clinical Trials
Light Chain Bioscience Successfully Completes Factor VIII Mimetic Bispecific Antibody Discovery
Light Chain Bioscience has achieved a milestone and received a payment under its research and collaboration agreement with Takeda Pharmaceutical. The milestone was achieved upon the successful completion of the discovery phase and designation by Takeda of undisclosed bispecific...
Clinical Trials
Chiesi Group Announces Establishment of New Global Rare Diseases Division
Chiesi Farmaceutici S.p.A., an international research-focused healthcare Group (Chiesi Group), announced the formation of Chiesi Global Rare Diseases, a new business unit that will harness the full resources of the Chiesi Group to advance research and new product development...
Clinical Trials
Iddi intensifies global debate on the future of randomized trials in Clinical Research
International Drug Development Institute (IDDI), a leading therapy-focused Biostatistics and eClinical Services corporation based in Belgium with offices in Boston (MA) and Raleigh (NC) announces that it is hosting a symposium to drive the debate: Are Randomized Clinical Trials...
Clinical Trials
AIVITA Biomedical completes patient enrollment target in phase 2 GBM trial for glioblastoma
AIVITA Biomedical, Inc., a biotech company specializing in innovative stem cell applications, announced that it has reached its patient enrollment target in the company's phase 2 clinical trial for glioblastoma. The trial has achieved its enrollment target ahead of...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read















